- Home
- HSII vs PRTA Comparison
HSII vs PRTA Comparison
Compare HSII & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSII
- PRTA
- Stock Information
- Founded
- HSII 1953
- PRTA 2012
- Country
- HSII United States
- PRTA Ireland
- Employees
- HSII N/A
- PRTA N/A
- Industry
- HSII Diversified Commercial Services
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- HSII Consumer Discretionary
- PRTA Health Care
- Exchange
- HSII Nasdaq
- PRTA Nasdaq
- Market Cap
- HSII 904.3M
- PRTA 809.8M
- IPO Year
- HSII 1999
- PRTA N/A
- Fundamental
- Price
- HSII $42.35
- PRTA $7.43
- Analyst Decision
- HSII Buy
- PRTA Buy
- Analyst Count
- HSII 2
- PRTA 9
- Target Price
- HSII $48.00
- PRTA $51.71
- AVG Volume (30 Days)
- HSII 139.5K
- PRTA 1.4M
- Earning Date
- HSII 05-05-2025
- PRTA 05-08-2025
- Dividend Yield
- HSII 1.42%
- PRTA N/A
- EPS Growth
- HSII N/A
- PRTA N/A
- EPS
- HSII 0.37
- PRTA N/A
- Revenue
- HSII $1,116,954,000.00
- PRTA $137,935,000.00
- Revenue This Year
- HSII $1.86
- PRTA N/A
- Revenue Next Year
- HSII $3.66
- PRTA $131.71
- P/E Ratio
- HSII $114.71
- PRTA N/A
- Revenue Growth
- HSII 6.10
- PRTA 54.55
- 52 Week Low
- HSII $30.20
- PRTA $8.00
- 52 Week High
- HSII $49.02
- PRTA $25.42
- Technical
- Relative Strength Index (RSI)
- HSII 61.05
- PRTA 24.16
- Support Level
- HSII $38.53
- PRTA $9.37
- Resistance Level
- HSII $41.12
- PRTA $8.80
- Average True Range (ATR)
- HSII 1.22
- PRTA 0.67
- MACD
- HSII 0.58
- PRTA -0.09
- Stochastic Oscillator
- HSII 68.80
- PRTA 16.19
About HSII Heidrick & Struggles International Inc.
Heidrick & Struggles International Inc is a leadership advisory firm providing executive search and consulting services to businesses and business leaders world wide. The company's operating segments includes the executive search business which operates in the Americas; Europe; Asia Pacific and On-Demand Talent and Heidrick Consulting. It generates maximum revenue from the Americas.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).